CytoSorbents Corporation (CTSO)

[Murph1953]

techxen Saturday, 03/02/19 09:42:44 AM
Post # 15342 of 18660
China is going all in on adsorbents

There have been several adsorbent technologies the Chinese have been developing over the past several years, but this is the first clinical trial that I have run across in China related to hemoadsorption and sepsis. This is a 144 patient trial which just started recruiting last month:

Efficacy and Safety Study of CA330 Hemoadsorption Device on IL-6 Removal in Septic Patients
https://clinicaltrials.gov/ct2/show/NCT03847961?term=cytosorb&rank=24

I thought it entertaining to see a statement in their study description bashing Cytosorb and Toraymyxin stating "...the clinical evidence to date supporting hemoadsorption for removal of endotoxins and/or proinflammatory mediators in sepsis remains incompetent and controversial."

This trial is using CA330 from Jafron Biomedical Co, a Chinese firm, and is supposed to be their improved version that targets more mid-molecular weight toxins and cytokines. Their earlier version HA330 only targeted low molecular weight toxins and was an activated charcoal and hyper-crosslinked adsorption resin and could not target cytokines.

The Chinese published a study back in 2017 comparing these adsorbents against NKU-9 which outperformed all of them including Cytosorb with faster and better adsorption rates. However, NKU-9 is no where near commercialization as is CA330. Take this published article for what its worth as it was funded by grants from National Natural Science Foundation of China.

High performance of a unique mesoporous polystyrene-based adsorbent for blood purification
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5274706/